OpGen Data Predicting Phenotypic Antimicrobial Susceptibility Published in Diagnostic Microbiology & Infectious Disease Journ...
23 March 2020 - 10:30PM
OpGen, Inc. (Nasdaq: OPGN) announced today that its Acuitas
Lighthouse® was used in a study conducted by the Mayo Clinic to
predict phenotypic resistance and antimicrobial susceptibility
among clinical isolates from the Antimicrobial Resistance
Leadership Group (ARLG). The findings were published in Diagnostic
Microbiology & Infectious Disease, a peer-reviewed scientific
journal providing the latest developments in clinical
microbiology and the diagnosis and treatment
of infectious diseases.
The manuscript titled ‘Core genome MLST and
resistome analysis of Klebsiella pneumoniae using a
clinically-amenable workflow,’ was authored by a team of
researchers at Mayo Clinic and others in the ARLG.
The manuscript showcases the use of core genome
multi locus sequence typing (cgMLST) and whole genome sequencing
(WGS) data, analyzed by OpGen’s Acuitas Lighthouse Software to
predict phenotypic antimicrobial susceptibility (AST). The analysis
was performed on forty (40), K. pneumoniae bacterial isolates from
the ARLG isolate collection. The overall agreement between
phenotypic AST and genotypic prediction was 95.6%.
“This research study is another important milestone for OpGen,
demonstrating the capabilities of Acuitas Lighthouse using Mayo
Clinic’s WGS data to predict phenotypic AST,” said Evan Jones, CEO
of OpGen. “Our Acuitas Lighthouse is versatile and has now been
shown to have utility with WGS data in addition to PCR test
results.”
For more information on Diagnostic Microbiology
& Infectious Disease, or to access the latest issue, please
click here.
About OpGen
OpGen, Inc. is a precision medicine company
harnessing the power of molecular diagnostics and informatics to
help combat infectious disease. We are developing molecular
information products and services for global healthcare settings,
helping to guide clinicians with more rapid and actionable
information about life threatening infections, improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. Our proprietary DNA
tests and informatics address the rising threat of antibiotic
resistance by helping physicians and other healthcare providers
optimize care decisions for patients with acute
infections.
Our molecular diagnostics and informatics
products, product candidates and services combine our Acuitas®
molecular diagnostics and Acuitas Lighthouse® informatics platform
for use with our proprietary, curated MDRO knowledgebase. We are
working to deliver our products and services, some in development,
to a global network of customers and partners. The Acuitas AMR Gene
Panel (RUO) is intended for Research Use Only and is not for use in
diagnostic procedures. The Acuitas Lighthouse Software is not
distributed commercially for antibiotic resistance prediction and
is not for use in diagnostic procedures. For more information,
please visit www.opgen.com.
OpGen, Acuitas, and Acuitas
Lighthouse are registered trademarks of OpGen, Inc.
Forward-Looking Statements
This press release includes statements relating
to use of OpGen’s Acuitas Lighthouse informatics platform by the
Antimicrobial Resistance Leadership Group (ARLG) and the Mayo
Clinic in a study to predict phenotypic resistance and
antimicrobial susceptibility of K. pneumoniae bacterial isolates.
These statements and other statements regarding OpGen’s future
plans and goals constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to
differ materially from expectations. Factors that could cause our
results to differ materially from those described include, but are
not limited to, our ability to successfully, timely and
cost-effectively develop, seek and obtain regulatory clearance for
and commercialize our product and services offerings, the rate of
adoption of our products and services by hospitals and other
healthcare providers, and other economic and competitive
factors. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please review our
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
OpGen Contact: Michael Farmer Vice President,
Marketing (240)
813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Press Contact:Matthew BretziusFischTank
Marketing and PRmatt@fischtankpr.com
Investor Contact: Joe Green Edison Group
jgreen@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024